In this issue
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
Jump to section
More in this TOC Section
Cited By...
- Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy
- Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir
- COVID-19 and AKI: Where Do We Stand?
- Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019
- The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis
- Outcomes of COVID-19 among Patients with End Stage Renal Disease on Remdesivir
- Remdesivir in COVID-19 Patients with Impaired Renal Function
- New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
- Management of COVID-19 in special populations with kidney disease
- Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
- Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study